Immunotherapy (Investigational)
19 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Immunotherapy (Investigational) (10)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
BMS-986156 (GITR) |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
BMS-986156 (GITR)
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
INCAGN1876 (GITR) |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
INCAGN1876 (GITR)
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
Ivonescimab |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
Ivonescimab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
MEDI1873 (GITR) |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
MEDI1873 (GITR)
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
Obrixtamig |
Bispecific T-Cell Engager, DLL3 x CD3 | Solid Tumour | ||
|
Molecule
Obrixtamig
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Bispecific T-Cell Engager, DLL3 x CD3 |
||||
Rilotumumab |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
Rilotumumab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
Tarlatamab |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
Tarlatamab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
Urelumab |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
Urelumab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
Utomilumab |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
Utomilumab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
Vopratelimab |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
Vopratelimab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
BMS-986156 (GITR)Immunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
INCAGN1876 (GITR)Immunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
IvonescimabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
MEDI1873 (GITR)Immunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
ObrixtamigImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Bispecific T-Cell Engager, DLL3 x CD3 |
|
RilotumumabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
TarlatamabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
UrelumabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
UtomilumabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
VopratelimabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|